BioCentury
ARTICLE | Clinical News

Arsanis discontinues Phase II of lead anti-infective

June 29, 2018 2:46 PM UTC

Arsanis Inc. (NASDAQ:ASNS) discontinued a double-blind, international Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint.

In a planned interim analysis, an independent data review committee found that IV ASN100 was unlikely to reduce the proportion of patients who develop S. aureus pneumonia through 21 days after a single dose vs. placebo. The trial was designed to evaluate ASN100's superiority to placebo in preventing the disease in about 354 high-risk, mechanically ventilated patients...

BCIQ Company Profiles

Arsanis Inc.